Significant response to tislelizumab plus bevacizumab in a patient with microsatellite instability-high colon cancer: A case report and review of literature
World Journal of Gastroenterology · 14.01.2027 · 33 (2)
DOI: 10.3748/wjg.124393 ↗Kurz gefasst
Fallbericht in der Zeitschrift World Journal of Gastroenterology, online erschienen am 14.01.2027. Verfasst von Yun-Fei Chen und 3 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Programmed cell death protein-1 inhibitors are established treatments for advanced microsatellite instability-high (MSI-H) colorectal cancer; however, primary and acquired resistance persist. Recent studies have indicated that combining programmed cell death protein-1 inhibitors with anti-angiogenic targeted agents has been explored as a strategy to improve responses; however, evidence for this approach in MSI-H colorectal cancer remains limited. CASE SUMMARY We present the case of a 58-year-old female patient with previous primary ovarian and gastric malignancies who was recently diagnosed with malignant adenocarcinoma of the descending and sigmoid colons (cT4N2M1, American Joint Committee on Cancer 8th edition). Exploration revealed signs of peritoneal metastasis. The primary tumor was unresectable, and a colostomy was performed for obstruction. Next-generation sequencing revealed a KRAS mutation and MSI-H. Germline testing revealed a pathogenic MSH2 c.1216C > T p (R406*) variant, leading to a diagnosis of Lynch syndrome. Because chemotherapy was unsuitable, she received 12 cycles of tislelizumab (200 mg) plus bevacizumab (400 mg) intravenously every 3 weeks as chemotherapy-free conversion therapy. The longest diameter of the target lesion decreased from 94 to 26 mm, confirming a partial response according to Response Evaluation Criteria in Solid Tumors 1.1, which was maintained at the most recent imaging assessment. No treatment modifications due to toxicity were documented. CONCLUSION This case highlights the potential feasibility of combining immune checkpoint inhibitors with anti-angiogenic agents to achieve a deep radiological response and improve patient prognosis, representing a therapeutic strategy that warrants further exploration.
Zitieren
APA
Chen, Y., Huang, C., Chen, Z., & Wang, Z. (2027). Significant response to tislelizumab plus bevacizumab in a patient with microsatellite instability-high colon cancer: A case report and review of literature. World Journal of Gastroenterology, 33(2). https://doi.org/10.3748/wjg.124393
Vancouver
Chen Y, Huang C, Chen Z, Wang Z. Significant response to tislelizumab plus bevacizumab in a patient with microsatellite instability-high colon cancer: A case report and review of literature. World Journal of Gastroenterology. 2027;33(2). doi:10.3748/wjg.124393
BibTeX
@article{Chen2027,
author = {Chen, Yun-Fei and Huang, Chi and Chen, Zhi-Jian and Wang, Zhi-Hui},
title = {Significant response to tislelizumab plus bevacizumab in a patient with microsatellite instability-high colon cancer: A case report and review of literature},
journal = {World Journal of Gastroenterology},
year = {2027},
volume = {33},
number = {2},
doi = {10.3748/wjg.124393}
}
EUVIMED